Created in 2015, VitaDX (Rennes, 12 employees) has developed a software for early detection of bladder cancer, which should be marketed from 2020. This algorithm is patent protected and developed for an international purpose.
Today, there are an estimated 430,000 new cases of bladder cancer a year in the world and it is the 6th most common cancer in France. If detected in time, the 5-year survival rate is greater than 95%.
The software required 5 years of R&D and a considerable financial investment to industrialise it thanks to a 1st round of financing of €1.2 M mid-2015 then a 2nd in 2017 of €1.6 M. A 3rd fundraising of €3 M is expected to take place by the 1st half of 2019 for its global business development. By then, clinical evidence should be established for Europe and the USA. The solution should be efficient and very competitive.
Source : Le Mag Numérique – 04/06/2018
Photo credit : VitaDX